Fierce Biotech3d
Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer
Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
Ono pays $280M to license Ionis rare disease drug
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
Business Wire3d
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
Fierce Pharma1d
Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Houston Press9d
Yoko Ono Gets Solo Bio
Of the thousands of books written by or about the Beatles and seemingly everyone in their orbit, it’s astonishing to think ...
‘Nervous and rushed': Massive Fukushima plant cleanup work involves high radiation and stress
The Fukushima Daiichi nuclear power plant’s radiation levels have significantly dropped since the cataclysmic meltdown 14 ...